ArticleThe pharmacogenomics journal2019
Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults.
Article in The pharmacogenomics journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Adverse Drug Reaction Costs and Study Quality in Africa: A Systematic Review of Cost-of-Illness Studies.PharmacoEconomics - open · 2026Pooled it
- Economic Burden of Inappropriate Antibiotic Prescribing Attributable to Dengue in Singapore.PharmacoEconomics - open · 2026Article
- Polypharmacy and adverse drug reactions among hospitalised children: determinants and clinical and economic impact in a multicentre prospective cohort and nested matched case-control study in Northwest Ethiopia.BMJ paediatrics open · 2026Article
- Economic Evaluation of Pre-emptive Pharmacogenetic Panel Testing versus No Genetic Testing in a Multi-ethnic Asian Population.PharmacoEconomics · 2026Article
- Breaking the Barrier of Brain Disease Therapeutics: Advocating Targeted Drug Delivery for Improved Neuro-Resident Interventions.AAPS PharmSciTech · 2026Review
- A feasibility study on implementing pre-emptive pharmacogenomics testing in outpatient clinics in Singapore (IMPT study).The pharmacogenomics journal · 2025Article
- Probing the in-depth analysis of Serious Adverse Drug Reactions in a tertiary care hospital of Central India.Exploratory research in clinical and social pharmacy · 2025Article
- A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care.The pharmacogenomics journal · 2024Review
- Article
- Article
- Access to Telepharmacy Services May Reduce Hospital Admissions in Outpatient Populations During the COVID-19 Pandemic.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2022Article
- Self-Efficacy, Social Activity, and Spirituality in the Care of Elderly Patients with Polypharmacy in Germany-A Multicentric Cross-Sectional Study within the HoPES3 Trial.Healthcare (Basel, Switzerland) · 2021Article
- Health outcomes and policy in pharmay curricula among Arab countries: An evaluation of 191 academic institutions.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021Article
- Progress in study on the association between HLA genetic variation and adverse drug reactions.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2021Article
- Genetics of Severe Cutaneous Adverse Reactions.Frontiers in medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Adverse drug reactions (ADRs) contribute to hospitalization but data on its economic burden is scant. Pre-emptive pharmacogenetic (PGx) testing can potentially reduce ADRs and its associated costs. The objectives of this study were to quantify the economic burden of ADRs and to estimate the breakeven cost of pre-emptive PGx testing in Singapore. We collected itemized costs for 1000 random non-elective hospitalizations of adults admitted to a tertiary-care general hospital in Singapore. The presence of ADRs at admission and their clinical characteristics were reported previously. The economic burden of ADRs was assessed from two perspectives: (1) Total cost and (2) incremental costs. The breakeven cost of PGx testing was estimated by dividing avoidable hospitalization costs for ADRs due to selected drugs by the number of patients taking those drugs. The total cost of 81 admissions caused by ADRs was US$570,404. Costs were significantly higher for bleeding/elevated international normalized ratio (US$9906 vs. US$2251, p = 6.58 × 10
Indexed as
Identifiers
30250149What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.